palbociclib isethionate

Palbociclib Isethionate (PD 0332991 isethionate) is a selective inhibitor of CDK4 6 (IC50s: 11 16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

Palbociclib (PD 0332991) dihydrochloride is an orally active, selective inhibitor of CDK4 (IC50: 11 nM) and CDK6 (IC50: 16 nM), exhibiting anti-proliferative activity and inducing cell cycle arrest in HR-positive and HER2-negative breast cancers and hepatocellular carcinoma studies.

Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

Palbociclib (PD 0332991) hydrochloride is a selective and potent inhibitor of CDK4 (IC50: 11 nM) and CDK6 (IC50: 16 nM). It exerts anti-proliferative effects on cancer cells, inducing cell cycle arrest, and can be used in research on HR-positive and HER2-negative breast cancer, as well as hepatocellular carcinoma.

Palbociclib D8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active inhibitor of CDK4 and CDK6 (IC50s of 11 and 16 nM, respectively).

Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.